CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL:Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF